A US Court of Appeals for the Federal Circuit on Tuesday upheld an earlier decision to delay the approval of Teva's generic version of Eli Lilly's Evista (raloxifene) until a patent-infringement trial over the osteoporosis drug begins on March 9. Teva was expected to be allowed to introduce a generic version of the drug in November 2008, but Eli Lilly obtained a court order preventing the FDA from approving Teva's formulation until the March trial starts. The judge in the case said the delay Raloxifene 10. September 2008 Evista (Raloxifene) is used to prevent and treat bone loss (osteoporosis) in women after menopause., Evista is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures. This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Ev
No comments:
Post a Comment